JP2019509976A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019509976A5 JP2019509976A5 JP2018528648A JP2018528648A JP2019509976A5 JP 2019509976 A5 JP2019509976 A5 JP 2019509976A5 JP 2018528648 A JP2018528648 A JP 2018528648A JP 2018528648 A JP2018528648 A JP 2018528648A JP 2019509976 A5 JP2019509976 A5 JP 2019509976A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- cdr
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021163120A JP7455787B2 (ja) | 2015-12-02 | 2021-10-01 | グリコシル化ｐｄ－１に対して特異的な抗体およびその使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562262303P | 2015-12-02 | 2015-12-02 | |
| US62/262,303 | 2015-12-02 | ||
| PCT/US2016/064394 WO2017096026A1 (en) | 2015-12-02 | 2016-12-01 | Antibodies specific to glycosylated pd-1 and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021163120A Division JP7455787B2 (ja) | 2015-12-02 | 2021-10-01 | グリコシル化ｐｄ－１に対して特異的な抗体およびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019509976A JP2019509976A (ja) | 2019-04-11 |
| JP2019509976A5 true JP2019509976A5 (https=) | 2020-01-16 |
| JP7003036B2 JP7003036B2 (ja) | 2022-02-04 |
Family
ID=58797717
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018528648A Active JP7003036B2 (ja) | 2015-12-02 | 2016-12-01 | グリコシル化ｐｄ－１に対して特異的な抗体およびその使用方法 |
| JP2021163120A Active JP7455787B2 (ja) | 2015-12-02 | 2021-10-01 | グリコシル化ｐｄ－１に対して特異的な抗体およびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021163120A Active JP7455787B2 (ja) | 2015-12-02 | 2021-10-01 | グリコシル化ｐｄ－１に対して特異的な抗体およびその使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US10858432B2 (https=) |
| EP (1) | EP3383412A4 (https=) |
| JP (2) | JP7003036B2 (https=) |
| KR (1) | KR102809728B1 (https=) |
| CN (1) | CN109152798B (https=) |
| WO (1) | WO2017096026A1 (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11933786B2 (en) | 2015-03-30 | 2024-03-19 | Stcube, Inc. | Antibodies specific to glycosylated PD-L1 and methods of use thereof |
| MX383464B (es) | 2015-07-13 | 2025-03-14 | Cytomx Therapeutics Inc | Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos. |
| AU2016317915B2 (en) | 2015-09-01 | 2021-02-18 | Agenus Inc. | Anti-PD-1 antibodies and methods of use thereof |
| WO2017055404A1 (en) | 2015-10-02 | 2017-04-06 | F. Hoffmann-La Roche Ag | Bispecific antibodies specific for pd1 and tim3 |
| JP7003036B2 (ja) * | 2015-12-02 | 2022-02-04 | エスティーキューブ，インコーポレイテッド | グリコシル化ｐｄ－１に対して特異的な抗体およびその使用方法 |
| CN109071636A (zh) * | 2016-03-29 | 2018-12-21 | 斯特库比股份有限公司 | 用于选择特异性结合糖基化免疫检查点蛋白的抗体的方法 |
| CN109715666B (zh) | 2016-07-20 | 2023-02-21 | 斯特库比股份有限公司 | 癌症治疗方法和使用结合糖基化pd-l1的抗体的组合的疗法 |
| CN110300599B (zh) | 2016-12-07 | 2024-07-02 | 艾吉纳斯公司 | 抗体和其使用方法 |
| EP3568157A4 (en) * | 2017-01-13 | 2021-01-06 | National Research Council of Canada | PROCESS FOR THE OPTIMIZATION OF PEPTIDIC IMMUNO-EPITOPE BY GLYCOSYLATION, ASSOCIATED OPTIMIZED PEPTIDE AND ITS USE FOR CONJUGATE VACCINES |
| MY201482A (en) | 2017-04-03 | 2024-02-26 | Hoffmann La Roche | Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15 |
| EP4516809A3 (en) | 2017-04-05 | 2025-09-03 | F. Hoffmann-La Roche AG | Bispecific antibodies specifically binding to pd1 and lag3 |
| CN111051346A (zh) | 2017-05-31 | 2020-04-21 | 斯特库伯株式会社 | 使用免疫特异性结合btn1a1的抗体和分子治疗癌症的方法 |
| KR20200026209A (ko) | 2017-06-06 | 2020-03-10 | 주식회사 에스티큐브앤컴퍼니 | Btn1a1 또는 btn1a1-리간드에 결합하는 항체 및 분자를 사용하여 암을 치료하는 방법 |
| AR114127A1 (es) | 2018-03-02 | 2020-07-22 | Lilly Co Eli | Anticuerpos agonistas contra pd-1 y usos de estos |
| CN112584901A (zh) * | 2018-04-04 | 2021-03-30 | 真和制药有限公司 | 用于阻断非糖基化的pd-1多肽之间的相互作用的方法和组合物 |
| US12448448B2 (en) | 2018-06-20 | 2025-10-21 | Incyte Corporation | Anti-PD-1 antibodies and uses thereof |
| CN111166867B (zh) * | 2018-11-09 | 2022-12-20 | 中国科学院分子细胞科学卓越创新中心 | Pd-1泛素化激动剂的功能与用途 |
| CN111423510B (zh) * | 2019-01-10 | 2024-02-06 | 迈威(上海)生物科技股份有限公司 | 重组抗人pd-1抗体及其应用 |
| JP6881658B2 (ja) | 2019-07-05 | 2021-06-02 | 小野薬品工業株式会社 | Ｐｄ−１／ｃｄ３二重特異性タンパク質による血液がん治療 |
| US20220332825A1 (en) | 2019-08-08 | 2022-10-20 | Ono Pharmaceutical Co., Ltd. | Bispecific protein |
| US20220411511A1 (en) * | 2019-09-26 | 2022-12-29 | Stcube & Co. | Antibodies specific to glycosylated ctla-4 and methods of use thereof |
| EP4041768A1 (en) | 2019-10-09 | 2022-08-17 | StCube & Co. | Antibodies specific to glycosylated lag3 and methods of use thereof |
| CN114316022A (zh) * | 2020-09-30 | 2022-04-12 | 正大天晴康方(上海)生物医药科技有限公司 | 结合pd-1抗体的肽及其应用 |
| KR20240005794A (ko) * | 2021-05-18 | 2024-01-12 | 쑤저우 카노바 바이오파마슈티컬 컴퍼니 리미티드 | 항 pd-1 폴리펩티드 및 그의 용도 |
| CN113372447A (zh) * | 2021-05-26 | 2021-09-10 | 重庆中元汇吉生物技术有限公司 | 抗pivka-ii单克隆抗体及其应用 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030148406A1 (en) | 1992-03-17 | 2003-08-07 | David John King | Multivalent antigen-binding proteins |
| CN101899114A (zh) * | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
| DE10303664A1 (de) | 2003-01-23 | 2004-08-12 | Nemod Immuntherapie Ag | Erkennungsmoleküle zur Behandlung und Detektion von Tumoren |
| US20080187954A1 (en) | 2004-03-10 | 2008-08-07 | Lonza Ltd. | Method For Producing Antibodies |
| WO2006004988A2 (en) | 2004-06-30 | 2006-01-12 | Mayo Foundation For Medical Education And Research | B7-dc binding antibody |
| US20090041783A1 (en) | 2005-04-28 | 2009-02-12 | Mochida Pharmaceutical Co., Ltd. | Anti-platelet membrane glycoprotein vi monoclonal antibody |
| DK2439273T3 (da) * | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| WO2007124361A2 (en) | 2006-04-20 | 2007-11-01 | Mayo Foundation For Medical Education And Research | Soluble b7-h1 |
| US20080118978A1 (en) | 2006-04-28 | 2008-05-22 | Takashi Sato | Anti-tumor agent |
| BR122017025062B8 (pt) * | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| US20100285039A1 (en) | 2008-01-03 | 2010-11-11 | The Johns Hopkins University | B7-H1 (CD274) Antagonists Induce Apoptosis of Tumor Cells |
| JP2012500855A (ja) * | 2008-08-25 | 2012-01-12 | アンプリミューン、インコーポレーテッド | Ｐｄ−１アンタゴニストおよび感染性疾患を処置するための方法 |
| US8552154B2 (en) | 2008-09-26 | 2013-10-08 | Emory University | Anti-PD-L1 antibodies and uses therefor |
| EP2198884A1 (en) | 2008-12-18 | 2010-06-23 | Centre National de la Recherche Scientifique (CNRS) | Monoclonal antibodies directed against LG4-5 domain of alpha3 chain of human laminin-5 |
| PL2504364T3 (pl) | 2009-11-24 | 2017-12-29 | Medimmune Limited | Ukierunkowane środki wiążące przeciwko B7-H1 |
| EP2542581A4 (en) | 2010-03-01 | 2014-01-22 | David Gladstone Inst | APOLIPOPROTEIN-SPECIFIC ANTIBODY AND METHOD OF USE THEREOF |
| BR112014003315A2 (pt) | 2011-08-15 | 2017-03-01 | Univ Chicago | composições e métodos relacionados a anticorpos para a proteína a estafilocócica |
| JP2015502340A (ja) | 2011-10-27 | 2015-01-22 | エヌケーティー セラピューティクス インコーポレーテッドＮｋｔ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | ｉＮＫＴに対するヒト化抗体 |
| KR101764096B1 (ko) | 2011-11-28 | 2017-08-02 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| CN104411720B (zh) * | 2012-07-02 | 2018-05-11 | 协和发酵麒麟株式会社 | 以抗bmp9抗体作为有效成分的、对肾性贫血、癌性贫血等贫血的治疗剂 |
| BR112015007672A2 (pt) | 2012-10-04 | 2017-08-08 | Dana Farber Cancer Inst Inc | anticorpos anti-pd-l1 monoclonais humanos e métodos de uso |
| CN112552401B (zh) | 2013-09-13 | 2023-08-25 | 广州百济神州生物制药有限公司 | 抗pd1抗体及其作为治疗剂与诊断剂的用途 |
| EP3060581A4 (en) | 2013-10-25 | 2017-06-07 | Dana-Farber Cancer Institute, Inc. | Anti-pd-l1 monoclonal antibodies and fragments thereof |
| SG10201804945WA (en) * | 2013-12-12 | 2018-07-30 | Shanghai hengrui pharmaceutical co ltd | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof |
| JP2017507900A (ja) | 2013-12-17 | 2017-03-23 | ジェネンテック， インコーポレイテッド | Ｐｄ−１軸結合アンタゴニスト及び抗ｈｅｒ２抗体を使用してｈｅｒ２陽性がんを治療する方法 |
| TWI681969B (zh) * | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| CN103897036B (zh) * | 2014-03-24 | 2016-02-24 | 郑州大学 | 一种pd-1蛋白胞外段亲和肽l8及其应用 |
| TWI595006B (zh) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗ｐｄ－１抗體類和使用彼等之方法 |
| WO2016160792A1 (en) * | 2015-03-30 | 2016-10-06 | Stcube & Co., Inc. | Antibodies specific to glycosylated pd-l1 and methods of use thereof |
| CN107852765B (zh) | 2015-07-29 | 2022-03-08 | 夏普株式会社 | 用于设备到设备中继过程的方法 |
| ES2895034T3 (es) * | 2015-10-02 | 2022-02-17 | Hoffmann La Roche | Anticuerpos anti-PD1 y procedimientos de uso |
| WO2017055404A1 (en) * | 2015-10-02 | 2017-04-06 | F. Hoffmann-La Roche Ag | Bispecific antibodies specific for pd1 and tim3 |
| JP7003036B2 (ja) | 2015-12-02 | 2022-02-04 | エスティーキューブ，インコーポレイテッド | グリコシル化ｐｄ－１に対して特異的な抗体およびその使用方法 |
-
2016
- 2016-12-01 JP JP2018528648A patent/JP7003036B2/ja active Active
- 2016-12-01 CN CN201680078477.9A patent/CN109152798B/zh active Active
- 2016-12-01 EP EP16871487.1A patent/EP3383412A4/en active Pending
- 2016-12-01 WO PCT/US2016/064394 patent/WO2017096026A1/en not_active Ceased
- 2016-12-01 US US15/778,663 patent/US10858432B2/en active Active
- 2016-12-01 KR KR1020187018671A patent/KR102809728B1/ko active Active
-
2020
- 2020-11-13 US US17/097,892 patent/US11981736B2/en active Active
-
2021
- 2021-10-01 JP JP2021163120A patent/JP7455787B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019509976A5 (https=) | ||
| US12060423B2 (en) | Humanized, mouse or chimeric anti-CD47 monoclonal antibodies | |
| US10081680B2 (en) | Anti-SIRP-alpha antibodies and bispecific macrophage enhancing antibodies | |
| JP2019502405A5 (https=) | ||
| CA3043691C (en) | Antibody binding specifically to cd66c and use thereof | |
| JP2021512604A5 (https=) | ||
| KR20250169224A (ko) | 암의 치료를 위한 항체, 또는 그의 항원-결합 단편의 조합물 및 그의 조성물 | |
| JP2019512210A5 (https=) | ||
| JP7811028B2 (ja) | ヒトｃｘｃｌ１６抗体およびその使用 | |
| CN120958025A (zh) | 针对含cub结构域的蛋白1(cdcp1)的抗体及其用途 | |
| JP2022552282A5 (https=) | ||
| TW202336033A (zh) | 抗體之新穎組合及用途 | |
| RU2022107092A (ru) | Новые анти-cldn18.2 антитела | |
| HK40040747A (en) | Humanized, mouse or chimeric anti-cd47 monoclonal antibodies | |
| HK1262017A1 (en) | Humanized, mouse or chimeric anti-cd47 monoclonal antibodies | |
| EA049228B1 (ru) | Набор для диагностики или иммунотерапии заболевания, ассоциированного с cd47 |